LIV by WellNow Review
Semaglutide GLP-1 weight-loss telehealth · Independently scored 5.9/10
Best for: compounded semaglutide at $279/month
LIV by WellNow's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
Not stated
Clinician visits
Not stated
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
One flat figure, $279 per month, buys the compounded semaglutide, the injection supplies and as many virtual visits as you want with board-certified online providers; approval comes same-day and the drug arrives monthly. WellNow Urgent Care owns LIV, its weight-management arm. To qualify you must be 18 or older with a BMI of 30+, or 27+ carrying a weight-related condition. FDA approval does not extend to compounded semaglutide. Five states get it: Pennsylvania, New York, Michigan, Indiana and Illinois. Insurance is refused.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to LIV by WellNow
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
LIV by WellNow at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Compounded semaglutide
- Starting price
- $279/mo
- Availability
- 5 states
- FDA status
- No FDA warning letter on record
How LIV by WellNow scores
Six columns, each one computed from something LIV by WellNow has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
2.2/10$279/month is 48% above the register median of $189 for compounded semaglutide.
Effectiveness25%
8.5/10Dispenses semaglutide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
8.5/10does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is high.
Accessibility10%
2.8/10Publishes coverage in 5 of 50 states.
Support10%
5.0/10States too little about what the monthly cost covers to score the bundle. Held at the midpoint rather than assumed.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on LIV by WellNow
Last checked June 2026- Re-read the price on file across 1 dose or plan tier
- Checked state coverage: 5 states
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: high.
What signing up with LIV by WellNow involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1LIV by WellNow publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3LIV by WellNow does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- Cheapest standing monthly prices on record: semaglutide $279. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for 5 of 50 states.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
GLP-1 medications LIV by WellNow offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Check the price yourself before you pay
Every figure here was read off LIV by WellNow's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- Semaglutide at $279 a month, 48% above the $189 register median for the same drug and form
- Coverage is published for 5 states only, so this may not reach you
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
What LIV by WellNow charges
LIV by WellNow charges $279/month. That sits above the middle of the market, which puts the burden on whatever else is in the package.
- Compounded semaglutide — $279/month
The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Check what is bundled before accepting it.
Direct Meds dispenses semaglutide from $249/month, which makes it the honest comparison to run before committing here.
What LIV by WellNow dispenses
LIV by WellNow prescribes semaglutide (approved as Wegovy and Ozempic). Between them these are among the best-evidenced options in this class. What arrives is compounded at a licensed pharmacy, not an approved pen. That is the reason it costs less, and the reason the finished preparation carries no FDA review behind it.
What we could verify
On the record: it operates in 5 states. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
Our read
LIV by WellNow costs more than the middle of this market. If the extras it charges for are ones you would actually use, that is a defensible trade. If not, the same molecule is available for less. MangoRx is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
LIV by WellNow's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay LIV by WellNow
Starting at $279/month. Check today's price, then book the free consultation.
Where LIV by WellNow is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this LIV by WellNow review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
See LIV by WellNow's current pricing
Plans start at $279/month. The free consultation is where you learn whether you qualify, and what it costs today.